Company news

Cellectar Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

February 14, 2023

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

November 29, 2022

Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

November 20, 2022

Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute

November 15, 2022

Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update

November 2, 2022

Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules

October 20, 2022

Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

September 21, 2022

Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

September 12, 2022

Cellectar Reports Financial Results for Second Quarter 2022

August 4, 2022

Cellectar Announces Stock Consolidation

July 20, 2022

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update

May 9, 2022

Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia

April 25, 2022

Cellectar Biosciences Announces Key Commercial Team Appointments

April 11, 2022

Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update

March 20, 2022

Cellectar Biosciences Announces Executive Leadership Changes

February 22, 2022

Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition

December 7, 2021

Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors

November 15, 2021

Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update

November 7, 2021

Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer

November 1, 2021

Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies

October 24, 2021

Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia

August 17, 2021

Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131

August 15, 2021

Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update

August 8, 2021

Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.

July 12, 2021

Cellectar Announces a Co-Development and Commercialization Collaboration with LegoChemBio for New Small Molecule Phospholipid Drug Conjugates (PDCs)

July 11, 2021

Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors

June 23, 2021

Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

May 19, 2021

Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update

May 9, 2021

Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico

April 26, 2021

Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates

March 8, 2021

Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update

March 1, 2021

Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia

January 26, 2021

Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

January 11, 2021

Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

December 27, 2020

Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement

December 22, 2020

Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement

December 21, 2020

Cellectar Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

November 8, 2020

Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors

November 4, 2020

Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients

September 8, 2020

Cellectar Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

August 9, 2020

Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting

August 3, 2020

Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

July 20, 2020

Cellectar Appoints Dr. John Friend as Chief Medical Officer

June 30, 2020

Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

June 10, 2020

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

June 4, 2020

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

June 2, 2020

Cellectar Granted SME Status by the European Medicines Agency

May 31, 2020

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

May 25, 2020

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

May 13, 2020

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 6, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.